Compare DBL & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DBL | CERS |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | EDP Services |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.5M | 276.0M |
| IPO Year | N/A | 1996 |
| Metric | DBL | CERS |
|---|---|---|
| Price | $14.38 | $2.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 47.0K | ★ 2.3M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $14.08 | $1.15 |
| 52 Week High | $16.01 | $3.15 |
| Indicator | DBL | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 54.87 |
| Support Level | $14.13 | $1.84 |
| Resistance Level | $14.59 | $2.91 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 49.98 | 43.55 |
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.